Randomized Trial Comparing Dose Reduction and Growth Factor Supplementation for Management of Hematological Side Effects in HIV/HCV Patients Receiving Pegylated-Interferon and Ribavirin

INTRODUCTION: Pegylated-interferon (PEG-IFN) and ribavirin (RBV), current standard treatment for hepatitis C virus (HCV) infection, is frequently associated with neutropenia and anemia, leading to high treatment discontinuation rates in HIV/HCV coinfected patients. Our objective was to compare the e...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Talal, Andrew H., Liu, Ruei-Chi, Zeremski, Marija, Dimova, Rositsa, Dove, Lorna, Pearce, Daniel, Hassanein, Tarek, Doonquah, Leleka, Aboulafia, David, Rodriguez, Jorge, Bonilla, Hector, Galpin, Jeffrey, Aberg, Judy A., Johnston, Barbara, Glesby, Marshall J., Jacobson, Ira M.
Format: Artigo
Idioma:Inglês
Publicat: 2011
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3386143/
https://ncbi.nlm.nih.gov/pubmed/21876446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0b013e3182324af9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars